Clinical Trial Update: Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the impact of hepatic impairment on the safety, tolerability, and pharmacokinetics of a single 200 mg dose of PF-868554.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PF-868554

Snippet

Sponsor: Pfizer | Conditions: HEPATITIS C (HCV) | Phase 1 | Status: COMPLETED